Milestone Pharmaceuticals Files 8-K on Financials

Ticker: MIST · Form: 8-K · Filed: May 14, 2025 · CIK: 1408443

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Milestone Pharma dropped an 8-K on May 14th covering their financials. Check it out.

AI Summary

Milestone Pharmaceuticals Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Montreal, Quebec.

Why It Matters

This filing provides an update on Milestone Pharmaceuticals' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not appear to contain any immediate or significant new risks.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is dated May 14, 2025.

Where are Milestone Pharmaceuticals Inc.'s principal executive offices located?

The principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, CA H4M 2X6.

What is the Commission File Number for Milestone Pharmaceuticals Inc.?

The Commission File Number is 001-38899.

What is the Standard Industrial Classification code for Milestone Pharmaceuticals Inc.?

The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding Milestone Pharmaceuticals Inc. (MIST).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing